Human epidermal growth factor 2 (HER2) is a ligand-free tyrosine kinase receptor of the HER 24 family that is overexpressed in some of the most aggressive tumours. Treatment of HER2+ breast 25 cancers with the humanized monoclonal anti-HER2 antibody (Trastuzumab) revealed highly 26 effective, encouraging the development of various HER2-specific antibodies, kinase inhibitors 27 and dimerization inhibitors for cancer therapy. Although it is known that HER2 dimerization 28 involves a specific region of its extracellular domain, the so-called "dimerization arm", the 29 mechanism of dimerization inhibition remains uncertain. However, uncovering how antibody 30 interactions lead to inhibition of HER2 dimerization is of key importance in understanding its role 31 in tumour progression and therapy. Herein, we employed several computational modelling 32 techniques for a molecular-level understanding of the interactions between HER and specific anti-
The human epidermal growth factor receptor (EGFR) family comprises four members: human 66 epidermal growth factor 1 (HER1), HER2, HER3 and HER4(1). They are overexpressed in a wide 67 variety of malignant tumours, in particular in Non-Small Cell Lung Cancer (NSCLC) (40-80 %), 68 breast cancer (14-91 %) and head and neck cancer (80-100 %) (2). In recent years, EGFR became 69 an important biomarker and target of anti-tumour therapy(3). Within the EGFR family, HER2 is 70 one of the most important members and when overexpressed, represents one of the most 71 aggressive phenotypes (approximately 20-25 % of invasive breast cancers)(4), making HER2 a 72 well-established therapeutic target. Trastuzumab (Herceptin ® ) was the first FDA-approved 73 antibody against HER2 and remains the gold standard for the treatment of HER2-overexpressing 74 cancers (5) . Clinical studies showed that the combination of trastuzumab with adjuvant 75 chemotherapy substantially improves disease-free survival (DFS) and overall survival(6).
76
From a structural point of view, HER2 is a 1255-amino-acid transmembrane glycoprotein with 77 185 kDa(7, 8) known for its function as a ligand-less co-receptor. It is noteworthy that HER2 is 78 the only member of the EGFR family that does not homodimerize under normal conditions, and 79 its ectodomain does not directly bind ligands (9) . It is activated via heterodimerization with other 80 ligand-bound receptors, with HER3 the preferred heterodimerization partner(10) or 81 homodimerization when it is expressed at very high levels on the cell surface(11). HER2 82 dimerization activates cytoplasmic kinase, which leads to autophosphorylation of its intracellular 83 domains and thereby downstream signalling of cellular pathways. In normal cells, few HER2 84 molecules exist at the cell surface, and therefore few heterodimers are formed, allowing growth 85 signals to be relatively weak and controllable. However, if HER2 is overexpressed, the 86 dimerization level increases, resulting in enhanced responsiveness to growth factors and 87 malignant growth(8). Structurally, HER2 comprises an extracellular domain (~600 amino acid 88 residues, Fig 1A) with four extracellular domains (ECD) (ECDI-ECDIV), including two cysteine 89 rich domains (ECDII and ECDIV), a transmembrane domain, an intracellular tyrosine kinase 90 domain and a C-terminal tail with autophosphorylation sites(12). 94 1N8Z(13) (A). The regions where both partners are located at the complex crystal structure are 95 also shown (B). The F0178:HER2 structure was obtained from PDBID: 3WSQ(14) whereas the 96 ScFv:HER2 structure was obtained from PDBID: 1N8Z(13). The secondary structure of the 97 receptor and its partners is depicted as a cartoon, and the surface is shown as a contour.
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The structures of the ligand-free HER2 ECDs (Fig 1A) , ECDI and ECDIII, are very similar, with 100 each containing a "β-helix" with sides, formed by three parallel β-sheets due to a high number of 101 hydrophobic residues, mainly leucine. The spatial conformation of these two subdomains hinders 102 the effective access in part explaining lack of ligand binding by HER2. ECDII and ECDIV also 103 share a similar structure with small structural units held together by one or two disulphide bonds.
104
ECDIV, a near transmembrane domain, is crucial to the stabilisation of the protein-protein 105 interactions between HER2 and its dimerization partner(15). The structural conformation of ECDI interaction between HER2 and other proteins(6).
130
In silico approaches are of crucial importance to clarify the structural and dynamical factors that 131 influence protein-protein interfaces (PPIs). They allow the prediction of how these interactions 132 occur, improving design and development of new therapeutic agents with better efficacies.
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Aiming at a detailed picture of the overall coupling mechanism between the different antibody 134 fragments and the receptor as well as to understand the HER2 dimerization process, we employed 135 computational modelling and Molecular Dynamics (MD) simulations of HER2 receptor in the 136 apo form and upon complexation with F0178 and scFv from trastuzumab. We performed an 137 undocumented systematic analysis of structural, energetic and dynamic characteristics, ranging 138 from pairwise interactions formation to covariance analyses for these complexes. Moreover, we 139 identified the most important changes occurring at these PPIs and their influence on the 140 conformational rearrangement of the specific domains involved in dimerization, which is key to 141 the development of new HER2-specific therapies.
143
Results 144
Reaching equilibration in the MD simulations 145
To attain equilibrium in MD simulations of large protein complexes is not a trivial task. We need 146 to evaluate the more conventional structural properties, like the root-mean-square deviation 147 (RMSD), but we will also need to monitor larger conformational transition of the quaternary 148 subunits that may appear at the slower timescales. The RMSD values were calculated using the 149 Cα atoms of the receptor, with either using all ECD regions, or excluding ECDIV (Fig 2) . The
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inclusion of the ECDIV region in the calculations greatly increased the overall RMSD value due 151 to its high conformational flexibility as can be observed in unbound HER2 and in the 152 F0178:HER2 complex (Fig 2A-B ). However, in ScFv:HER2, the contribution of ECDIV is 153 reduced, which was assigned to the strong interaction of the ScFv with this region ( Fig 1B) .
154
Overall, the ECDI-III region equilibrates relatively fast, while the ECDIV RMSD values indicate 155 larger movements occurring at larger timescales but of more difficult equilibration. 
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To investigate the slower conformational transitions between HER2 and its partners, we have also 164 calculated the centre-of-mass (COM) distance between them. This distance is almost invariant in 165 F0178:HER2 ( Fig S01) , since F0178 is interacting directly with the ECDI-ECDIII region of 166 HER2 ( Fig 1B) , inducing no significant domain movement. In the ScFv:HER2 system ( Fig S02) ,
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we observed that the ScFv, upon binding, induced an opening/closing movement of the ECDIV 168 towards the ECDI-III domains. As described in the methods section, this movement, which varies 169 in the hundreds of nanoseconds time scale, was the reason why we have extended the MD 170 simulations to improve its sampling.
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Brought together these results showed that ScFv position varies between two extremes, depending 173 on receptor proximity (Fig 3) . The maximum COM distance leads to an opening of the cleft 174 between ScFv and the HER2 ECDI-III domains ( Fig 3A) , an intermediate position, which is 175 similar to the initial conformation ( Fig 3B) ; and a minimum distance, which leads to cleft closure 176 and a direct interaction of ScFv with ECDI-III ( Fig 3C) . Next, we selected the equilibrated regions 177 of the MD simulations based on the RMSD and COM distances data. In the HER2 control and 178 the F0178:HER2 complex simulations, these equilibrated rather fast (30-50 ns), whereas in the 179 ScFv:HER2 system, due to the large domain movements, some replicates took up to 150 ns to 180 reach equilibrium. In this system, all replicates seemed to converge to a different COM distance,
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indicating that the use of multiple replicates was crucial to improve the sampling of this 182 movement. After the equilibration evaluation of the MD simulations, we identified the equilibrium 191 conformational space and performed a deeper analysis of HER2 conformation reorganisation after 192 antibody binding. Briefly, it has been previously described that HER2-ECDII is the main domain 193 involved in the dimerization process (19, 21) . Therefore, we have used an integrated approach of 194 multiple methods to evaluate how HER2 coupling to its different partners could alter this 195 functional mechanism. In addition, we have performed cross-correlation analysis for both 196 complexes (Fig 4) . For the unbound HER2 ( Fig 4A) 
212
Another very interesting aspect is the positive correlation between ECDIII and ECDII (187-363 213 region).
C Concerning ScFv:HER2 ( Fig 4C) , a strong positive correlation between ECDIV tail (above 800) 215 and ECDI and ECDII revealed the importance of ECDIV on the ScFv:HER2 interaction. The 216 strong negative correlation of ECDII and ECDIII, as opposed to HER2 movement when is 217 unbounded ( Fig 4A) suggested a conformational change with scFv binding at ECDIV. This 220
To extract the relevant information from the conformational rearrangement observed during the 221 MD simulations, we performed a PCA analysis for the F0178:HER2 and ScFv:HER2 systems.
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These calculations were performed using all replicas and considering only the equilibrated regions contribution to the first two principal components ( Fig 5B) . We also calculated the conservation 243 scores using the ConSurf web-server (22). Fig S03 shows a high conservation score for GLU352,
244
VAL353 and ARG354 at F0178:HER2 complexes, which is in accordance with the higher 245 contribution of ECDII region for PC1.
246
PCA analyses suggested two main conformational states for the scFv: HER2 MD simulations (Fig   247  5C ). In particular, the contribution of the ECDII residues to PC1 and PC2 ( Fig 5D) suggested that 248 the dimerization region was indeed affected by binding. Fig S03 also supports this behaviour with 249 a high rate of the conservation pattern at ECDII, namely at dimerization arm (GLU265-ARG288).
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Paradoxically, the role of the ECDII-HER2 residues in the interface-interaction network of both 251 complex systems were not considered in the literature (13, 14) . To further aid interpretation, we
iii) iv) produced a trajectory that interpolates between the most dissimilar structures in the distribution 253 along PC1 for both systems (Fig S04) . The movement of the "dimerization arm" at ECDII is rather 254 evident, as well as at ECDI. The role of this region for HER2 coupling mechanism has not been 255 previously described although the blocking ability of HER2 heterodimerization is well 256 recognised (14). We propose that the HER2 ECDII conformational change is coupled with this 257 allosteric regulation of F0178:HER2.
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Concerning the scFv:HER2 complex system, we observed an approximation between ECDII and 259 scFv compared to the initial 3D crystallographic structure (PDBID 1NZ8(13)) ( Fig S04) . This is 260 an important biological feature since it is well-known that the 'heart-shaped' domain II open 261 conformation is essential for dimerization 17 . 269 Therefore, we calculated the solvent accessible surface area (SASA) of each HER2 residue in all 270 systems to calculate significant differences between complexes and the unbound receptor. The
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residues with significant differences in SASA (difference > 5 % and standard error is smaller than 272 the difference value) due to the presence of a partner are associated with a direct interaction and 273 should correlate well with the interfacial region ( Fig 6) . As expected, the residues with the largest 274 shift in SASA in F0178:HER2 are located in ECDI, ECDII and ECDIII ( Fig 1B and Fig 6A) ,
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whereas in ScFv:HER2 these residues are mainly located in ECDII and ECDIV ( Fig 1B and Fig   276  6B ). In the case of ScFV:HER2, the direct interaction of the ligand with ECDII is due to the cleft 277 closure ( Fig 3C) , observed in several simulations ( Fig S02) . The large error bars in F0178:HER2
278 were attributed to insufficient sampling and/or an increase variability in the interfacial region of 279 the complex. 
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We also identified several residues whose SASA changed between unbound HER2 and its 286 complexes through an indirect, or allosteric, effect of the antibody fragment. This was attained by 287 calculating the SASA differences between F0178:HER2/ScFv:HER2 and HER2 trajectories,
288
ignoring the physical presence of the ligands. The residues identified with this procedure (Fig 7   289 and Fig S05) were different in both complexes, but located predominantly in ECDII, including 290 the so-called "dimerization arm" region (TYR274, GLU280 and MET282 in F0178:HER2; and 291 CYS268 in ScFv:HER2).
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Our results indicate that F0178 and scFv form fairly distinct dynamic complexes with HER2. The 293 binding of F0178 seems to provoke a marked allosteric effect on the "dimerization arm" residues 294 at ECDII, which is the dimerization region of HER2(16). A similar allosteric effect could be 295 observed for scFv, which was complemented with a direct interaction with the ECDII region.
296
This interaction map obtained from our simulations may help explain the strong effect of scFv on 297 HER2 homodimerization (6) 
323
In addition to the detailed residue and pairwise interaction analyses of HER2-antibody complexes,
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an important contribution of our work is on the conformational changes that occur upon binding.
325
Our simulations suggested that F0178 and scFv form distinct dynamic complexes with HER2.
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The binding of F0178 seems to induce a marked allosteric effect on the "dimerization arm", 
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Simulations were performed in the NPT (isothermal-isobaric) ensemble. Temperature coupling 357 was performed using the v-rescale thermostat(35) at 300 K, with a coupling constant of 0.1 ps, while an isotropic 37) was used to keep the pressure constant at 359 1 bar using a coupling constant of 2.0 ps and a compressibility of 4.5  10 5 bar 1 . Long range 360 electrostatic interactions were computed using the particle mesh Ewald (PME) method (38, 39) 361 with a Fourier grid spacing of 0.16 nm and a cut-off of 1.0 nm for direct contributions. Lennard-
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Jones interactions were computed using a nonbonded neighbour pair list with a cut-off of 1.0 nm, 363 enabling the use of the Verlet scheme (40). Solute bonds were constrained using the Parallel
364
LINear Constraint Solver, P-LINCS (41), and solvent molecules were constrained using SETTLE 365 algorithm(42). The initial system energy was first minimised for 50.000 steps, followed by two 366 equilibrations of 250 ps. The HER2 system was then initialised for 10 ps using position restraints 367 on all protein heavy atoms with a force constant of 1000 kJ nm 2 mol 1 , while the remaining 368 systems were initialised for 25 ps without restraints.
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Initially, four production runs were performed for each system, each 200 ns-long. In addition, for 370 the F0178:HER2 and ScFv:HER2 complexes, a longer production run was also performed (~500 371 ns-long). However, when analysing the centre-of-mass (COM) distance between the partners in 372 the HER2:ScFv system ( Fig S02) , we decided to extend the length of all production runs to 500 373 ns, in order to obtain better sampling of this motion.
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The equilibrated regions for each system (Table S03 , in the Supporting Information) was 375 replicate/system dependent, and the decision was based on the RMSD and COM distance 376 variations. The RMSD calculations were performed using the Cα atoms either in all extracellular 377 domains, or in the ECDI-ECDIII region, as shown in Fig 2. The COM distance plots (Fig 3 and 378 Figs S01-02) were obtained by calculating the centre-of-mass of the HER2 and either ScFv or 379 F0178, using all atoms in the receptor and each of its partners. We calculated the solvent-accessible surface area (SASA) of each individual residue in HER2,
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ScFv:HER2 and F0178:HER2 using the equilibrated regions of each replicate. In the unbound 385 used to calculate the mean and standard error of the mean (SEM) using a jackknife technique. We 386 then converted these absolute SASA values into percentages by calculating the maximum value 387 a fully exposed residue of each type would have. With these percentages, we excluded all residues 388 whose solvent-access was below 20 %, as they were considered mainly internalised. The identification of residues in the interface between HER2 and each of its partners was 392 performed by calculating the SASA of each residue of the receptor in the complex, with and 393 without its partner (e.g., the residue coloured in yellow depicted in Fig S06) . When comparing 394 the SASA values of each complex in the presence and absence of the antibody, we were able to 395 exclude all residues whose SASA was not altered, i.e. residues which are not interacting directly 396 with the partner. Finally, we only reported residues whose difference in SASA was above 5 % 397 and whose SEM was lower than this difference.
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SASA analysis of allosterically modulated residues 400
To identify allosterically modulated residues, we compared the SASA of all residues in each 401 complex with the same residue in unbound HER2. This SASA difference identified which 402 residues became more exposed or occluded by an indirect effect of the antibody (e.g. the residue 403 coloured in green depicted in Fig S06) . As in the previous protocol, residues whose difference in 404 SASA between systems was below 5 % and whose SEM was higher than the difference itself 405 were excluded. 590 Fig S05 - Location of the residues that showed a significant shift in SASA due to allosteric 591 effects. The regions coloured in red show the residues in HER2 whose SASA was affected by the 592 presence of ScFv, while the regions in blue show the residues in HER2 whose SASA was affected 593 by F0178. Also shown are the initial positions of both partners (semi-transparent). The image on 594 the right is the mirror-image of the one on the left. The secondary structure of the receptor and its 595 partners is depicted as a cartoon, and the surface is also shown as a contour. 
